Key points are not available for this paper at this time.
Meeting updates prioritize QT and CNS safety signals; leaves open translation of novel GI/renal methods to candidate selection.
The Safety Pharmacology (SP) Society annual meeting discussed organ and physiological system safety issues encountered during the course of clinical candidate selection and evaluation for human testing. Plenary sessions were dedicated to embryonic stem cell opportunities, successes, threats and new opportunities of SP, and the remembrance of our forever gone colleague, Dr Munehiro Hashimoto. The day-long QT interval liability session, attended by the majority of the 472 meeting participants, covered all the current facets of this topic with undeniable expertise, but limited novel data. CNS subjects of interest were drug dependence and abuse potential, a behavioural model of tinnitus, the use of electroencephalography in SP and the translation of nonclinical pro-convulsive signals into clinical trial management. Gastrointestinal and renal SP were also discussed in terms of novel experimental approaches. New horizon sessions addressed biowarfare and biodefence, enabling technologies for key decision-making in initial clinical testing and the future of SP. Thus, a wide spectrum of material for both education and reflection was offered to veteran and younger investigators desiring to further their knowledge in current SP themes.
No takes yet. Share an insight, caveat, or question.
Icilio Cavero (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: